EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma

Özge Ç Şener, Susanne Melchers, Luisa Tengler, Paul L Beltzig, Jana D Albrecht, Deniz Tümen, Karsten Gülow, Jochen S Utikal, Sergij Goerdt, Tobias Hein, Jan P Nicolay

Leukemia · 2025-02 · 39 (2) · 438-450

DOI: 10.1038/s41375-024-02479-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, online erschienen am 23.11.2024. Verfasst von Özge Ç Şener und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/ University of Heidelberg, Mannheim, Germany. Hauptthemen laut MEDLINE: Photopheresis, Lymphoma, T-Cell, Cutaneous, Dimethyl Fumarate, Skin Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung (Wilhelm Sander Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary cutaneous T cell lymphomas (CTCL) are characterized by high relapse rates to initially highly effective therapies. Combination therapies have proven beneficial, particularly if they incorporate extracorporeal photopheresis (ECP). The NF-κB inhibitor dimethyl fumarate (DMF) has proven a new, effective drug in CTCL in a clinical phase II study. In vitro experiments with patient-derived SS cells and the CTCL cell lines HH, HuT 78, and SeAx revealed a synergistic effect of DMF and ECP on cell death induction in CTCL cells. Furthermore, an additional increase in the capacity to inhibit NF-κB in CTCL was detected for the combination treatment compared to DMF monotherapy. The same synergistic effects could be measured for ROS production via decreased Thioredoxin reductase activity and glutathione levels. Consequently, a cell death inhibitor screen indicated that the DMF/ECP combination treatment induces a variety of cell death mechanisms in CTCL. As a first step into clinical translation, 4 patients were already treated with the DMF/ECP combination therapy with an overall response rate of 100% and a time to next treatment in skin and blood of up to 57 months. Therefore, our study introduces the combination treatment of DMF and ECP as a highly effective and long-lasting CTCL therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotopheresisLymphoma, T-Cell, CutaneousDimethyl FumarateSkin NeoplasmsHumansCombined Modality TherapyMaleCell DeathFemaleMiddle AgedRemission InductionCell Line, TumorNF-kappa BAgedReactive Oxygen Species

Substanzen

Dimethyl FumarateNF-kappa BReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/ University of Heidelberg, Mannheim, Germany.
  • Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious diseases, University Hospital Regensburg (UKR), Regensburg, Germany.
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
  • Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/ University of Heidelberg, Mannheim, Germany. jan.nicolay@umm.de.

Förderung

  • Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)

Zitieren

APA

Şener, Ö. Ç., Melchers, S., Tengler, L., Beltzig, P. L., Albrecht, J. D., Tümen, D., Gülow, K., Utikal, J. S., Goerdt, S., Hein, T., & Nicolay, J. P. (2025). Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma. Leukemia, 39(2), 438-450. https://doi.org/10.1038/s41375-024-02479-1

Vancouver

Şener ÖÇ, Melchers S, Tengler L, Beltzig PL, Albrecht JD, Tümen D, et al. Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma. Leukemia. 2025;39(2):438-450. doi:10.1038/s41375-024-02479-1

BibTeX
@article{ener2025,
  author = {Şener, Özge Ç and Melchers, Susanne and Tengler, Luisa and Beltzig, Paul L and Albrecht, Jana D and Tümen, Deniz and Gülow, Karsten and Utikal, Jochen S and Goerdt, Sergij and Hein, Tobias and Nicolay, Jan P},
  title = {Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma},
  journal = {Leukemia},
  year = {2025},
  volume = {39},
  number = {2},
  pages = {438--450},
  doi = {10.1038/s41375-024-02479-1}
}
Kostenlos starten →